These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 19860612)

  • 1. Random serum methotrexate determinations for assessing compliance with maintenance therapy for childhood acute lymphoblastic leukemia.
    Jaime-Pérez JC; Gómez-Almaguer D; Sandoval-González A; Chapa-Rodríguez A; Gonzàlez-Llano O
    Leuk Lymphoma; 2009 Nov; 50(11):1843-7. PubMed ID: 19860612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum creatinine and creatinine clearance for predicting plasma methotrexate concentrations after high-dose methotrexate chemotherapy for the treatment for childhood lymphoblastic malignancies.
    Xu WQ; Zhang LY; Chen XY; Pan BH; Mao JQ; Song H; Li JY; Tang YM
    Cancer Chemother Pharmacol; 2014 Jan; 73(1):79-86. PubMed ID: 24158402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Importance of oral antimetabolite "maintenance" therapy in childhood lymphoblastic leukemia.
    Lilleyman JS
    Pediatr Hematol Oncol; 1996; 13(5):vii-x. PubMed ID: 10897808
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia.
    Csordas K; Hegyi M; Eipel OT; Muller J; Erdelyi DJ; Kovacs GT
    Anticancer Drugs; 2013 Feb; 24(2):189-97. PubMed ID: 23187460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.
    Joannon P; Oviedo I; Campbell M; Tordecilla J
    Pediatr Blood Cancer; 2004 Jul; 43(1):17-22. PubMed ID: 15170885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Digestive disease in the immunocompromised patient with acute lymphoblastic leukemia. Experience of the IVth Pediatric Clinic--Oncology Department of the Iaşi Sfânta Maria Children's Hospital].
    Moisă SM; Rusu A; Dumitraş S; Burlea M; Miron I
    Rev Med Chir Soc Med Nat Iasi; 2008; 112(2):356-65. PubMed ID: 19295004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia and lymphoma.
    Nakano T; Kobayashi R; Matsushima S; Hori D; Yanagi M; Suzuki D; Kobayashi K
    Int J Hematol; 2021 May; 113(5):744-750. PubMed ID: 33389654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between a microRNA binding site polymorphism in SLCO1A2 and the risk of delayed methotrexate elimination in Chinese children with acute lymphoblastic leukemia.
    Wang SM; Zeng WX; Wu WS; Sun LL; Yan D
    Leuk Res; 2018 Feb; 65():61-66. PubMed ID: 29306656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of compliance through specific interviews: a prospective study of 73 children with acute lymphoblastic leukemia].
    de Oliveira BM; Viana MB; de Mattos Arruda L; Ybarra MI; Romanha AJ
    J Pediatr (Rio J); 2005; 81(3):245-50. PubMed ID: 15951910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of serum methotrexate concentrations and drug dosage on outcome in childhood acute lymphoblastic leukaemia.
    Pearson AD; Amineddine HA; Yule M; Mills S; Long DR; Craft AW; Chessells JM
    Br J Cancer; 1991 Jul; 64(1):169-73. PubMed ID: 1854617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative study of the long term psychosocial functioning of childhood acute lymphoblastic leukemia survivors treated by intrathecal methotrexate with or without cranial radiation.
    Hill JM; Kornblith AB; Jones D; Freeman A; Holland JF; Glicksman AS; Boyett JM; Lenherr B; Brecher ML; Dubowy R; Kung F; Maurer H; Holland JC
    Cancer; 1998 Jan; 82(1):208-18. PubMed ID: 9428499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of polymorphisms in transporter genes on dosing, efficacy and toxicity of maintenance therapy in children with acute lymphoblastic leukemia.
    Gervasini G; de Murillo SG; Jiménez M; de la Maya MD; Vagace JM
    Gene; 2017 Sep; 628():72-77. PubMed ID: 28710036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia.
    Lopez-Lopez E; Martin-Guerrero I; Ballesteros J; Piñan MA; Garcia-Miguel P; Navajas A; Garcia-Orad A
    Pediatr Blood Cancer; 2011 Oct; 57(4):612-9. PubMed ID: 21387541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of MTHFR C677T polymorphism and plasma pharmacokinetics to predict methotrexate toxicity in patients with acute lymphoblastic leukemia.
    Mahmoud LB; Mdhaffar M; Frikha R; Ghozzi H; Hakim A; Sahnoun Z; Elloumi M; Zeghal K
    Adv Clin Exp Med; 2018 Aug; 27(8):1061-1068. PubMed ID: 29911750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy, side effects and blood concentration monitoring of high-dose methotrexate in treatment of 180 children with acute lymphoblastic leukemia].
    Wang H; Chi ZF; Li S; Wang XL; Hao LC
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):949-52. PubMed ID: 21867621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and validation of LC-MS/MS assay for the simultaneous determination of methotrexate, 6-mercaptopurine and its active metabolite 6-thioguanine in plasma of children with acute lymphoblastic leukemia: Correlation with genetic polymorphism.
    Al-Ghobashy MA; Hassan SA; Abdelaziz DH; Elhosseiny NM; Sabry NA; Attia AS; El-Sayed MH
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Dec; 1038():88-94. PubMed ID: 27802917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Methotrexate-induced interstitial pneumonitis in a child with acute lymphoblastic leukemia].
    Tatsumoto C; Kawakami K; Nagayama J; Kawano H
    Rinsho Ketsueki; 2004 Oct; 45(10):1100-4. PubMed ID: 15553044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral methotrexate/6-mercaptopurine may be superior to a multidrug LSA2L2 Maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
    Schmiegelow K; Heyman M; Kristinsson J; Mogensen UB; Rosthøj S; Vettenranta K; Wesenberg F; Saarinen-Pihkala U;
    J Pediatr Hematol Oncol; 2009 Jun; 31(6):385-92. PubMed ID: 19648786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensification with intermediate-dose intravenous methotrexate is effective therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study.
    Mahoney DH; Shuster JJ; Nitschke R; Lauer S; Steuber CP; Camitta B
    J Clin Oncol; 2000 Mar; 18(6):1285-94. PubMed ID: 10715299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The interaction of 6-mercaptopurine (6-MP) and methotrexate (MTX).
    Giverhaug T; Loennechen T; Aarbakke J
    Gen Pharmacol; 1999 Oct; 33(4):341-6. PubMed ID: 10523073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.